Value
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 7.4 |
| P/S | 9.9 |
| EV/EBITDA | 5.2 |
| Fwd P/E | 9.2 |
| PEG | 6.1 |
| Analyst target | 6.0 |
- ▸Forward P/E: 10.6x
- ▸PEG: 1.22
- ▸Attractively valued
OPCH · Why this verdict
Why Option Care Health (OPCH) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Option Care Health offers attractive valuation and consistent earnings execution, but heavy customer and supplier concentration alongside declining earnings estimates and a confirmed downtrend keep the risk profile elevated.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With a forward price-to-earnings of 10.4x and a PEG ratio of 1.19, the stock trades at a meaningful discount relative to its earnings growth trajectory. Valuation breakdown | The forward price-to-earnings remains below 14x and earnings estimates stabilize or rise over the next 12 months. | Tripped→Stable |
| CounterLow valuations in healthcare services often reflect structural margin pressure from payer mix shifts rather than temporary mispricing. | ||
Managed care organizations and non-governmental payers account for 88% of revenue, concentrating the business in a small number of payer relationships that could reprice or terminate contracts. Bear case | Revenue from any single payer relationship does not exceed 40% of total revenue within the next 12 months. | ↓Deteriorating |
| CounterDeep integration with large managed care organizations creates switching costs that reduce the probability of abrupt contract losses. | ||
Earnings estimates are trending downward, signaling that consensus expectations for future profitability are being revised lower, which typically precedes price underperformance. Bear case | Earnings estimate revisions turn positive with at least 2 consecutive upward revisions to forward estimates within 12 months. | ↓Deteriorating |
| CounterThe company has beaten or matched estimates in all 4 recent quarters with a 3.6% average positive surprise, suggesting the downward revisions may be conservative. | ||
Despite the overall downtrend, the MACD is improving and on-balance volume is rising, suggesting that momentum may be transitioning toward recovery. Momentum breakdown | Price crosses above the 200-day moving average and sustains that level for at least 30 days within 12 months. | ↓Deteriorating |
| CounterThe moving average slope is declining at 4.0% over 30 days, which is a steep confirmed downtrend that can persist for many months. | ||
With a forward price-to-earnings of 10.4x and a PEG ratio of 1.19, the stock trades at a meaningful discount relative to its earnings growth trajectory.
Tripped→StableValuation breakdown
- Expectation
- The forward price-to-earnings remains below 14x and earnings estimates stabilize or rise over the next 12 months.
CounterLow valuations in healthcare services often reflect structural margin pressure from payer mix shifts rather than temporary mispricing.
Managed care organizations and non-governmental payers account for 88% of revenue, concentrating the business in a small number of payer relationships that could reprice or terminate contracts.
↓DeterioratingBear case
- Expectation
- Revenue from any single payer relationship does not exceed 40% of total revenue within the next 12 months.
CounterDeep integration with large managed care organizations creates switching costs that reduce the probability of abrupt contract losses.
Earnings estimates are trending downward, signaling that consensus expectations for future profitability are being revised lower, which typically precedes price underperformance.
↓DeterioratingBear case
- Expectation
- Earnings estimate revisions turn positive with at least 2 consecutive upward revisions to forward estimates within 12 months.
CounterThe company has beaten or matched estimates in all 4 recent quarters with a 3.6% average positive surprise, suggesting the downward revisions may be conservative.
Despite the overall downtrend, the MACD is improving and on-balance volume is rising, suggesting that momentum may be transitioning toward recovery.
↓DeterioratingMomentum breakdown
- Expectation
- Price crosses above the 200-day moving average and sustains that level for at least 30 days within 12 months.
CounterThe moving average slope is declining at 4.0% over 30 days, which is a steep confirmed downtrend that can persist for many months.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 5.1 |
| ROA | 4.1 |
| Gross margin | 0.0 |
| Op margin | 2.1 |
| Net margin | 1.8 |
| Current ratio | 5.9 |
| FCF quality | 6.1 |
| Moat | 4.2 |
| Piotroski F | 7.8 |
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 7/9
Growth
2.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.8 |
| EPS growth | 2.7 |
Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.6 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 1.1 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -3.5%/30d — confirmed downtrend
Sentiment
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 8.6 |
| erm sentiment | 4.4 |
- ▸Analyst upside: 30%
Insider
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider buying — $1,875,225 (0.055% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.5 |
| quality rank | 4.8 |
| growth rank | 1.4 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.2 |
| support resistance | 4.5 |
| 52w position | 1.8 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.1 |
| days to cover | 5.2 |
| volatility | 5.3 |
| put call | 1.0 |
| implied vol | 0.3 |
| beta | 9.1 |
| debt equity | 5.4 |
- ▸Elevated put/call: 1.86
- ▸High IV: 78%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 4.3 |
- ▸Earnings in 1 days
How the verdict was assembled
Engine trigger
Earnings in 1 day. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCKPassed (5)
- ASYMMETRY:2.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:3.2<4.5
- DEATH_CROSS:HARD_BLOCK
- EARNINGS_PROXIMITY:1d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
2.22
Upside
+12.8%
Downside
5.8%
Sizing output
STARTER
SetupRange Bound — RSI 54 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -41% (>40% off 52w high)
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings in 1 day. Wait until post-earnings. The 10-dimension scores remain Insider at 7.9 (strongest), but MOMENTUM:3.2<4.5 also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Insider at 7.9, Value at 7.3, and Sentiment at 6.9; the weakest are Growth at 2.8, Momentum at 3.2, and Technical at 3.5. The V9 engine flagged 3 failed gates with 1 warning, producing an asymmetric reward-to-risk of 2.22 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Attractive Valuation EntryTripped
Trip ifForward price-to-earnings rises above 14x due to earnings estimate cuts below current levels.
- P2Customer Concentration Risk
Trip ifRevenue from managed care payers exceeds 95% of total revenue for any reported period.
- P3Earnings Estimates Declining
Trip ifConsensus forward earnings estimates decline by more than 15% from current levels.
- P4Technical Recovery Setup
Trip ifPrice drops below $19 (below current stop-loss of $19.81) confirming trend continuation.